Anti-CCR8 monoclonal antibodies and therapeutic uses thereof

CN120476141APending Publication Date: 2025-08-12DOMAIN THERAPEUTICS SA
View PDF 35 Cites 0 Cited by

Patent Information

Application Number
CN202380080110.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-09-21
Filing Date
2023-09-21
Publication Date
2025-08-12

Smart Images

  • Figure BDA0005408318480000281
    Figure BDA0005408318480000281
  • Figure BDA0005408318480000291
    Figure BDA0005408318480000291
  • Figure BDA0005408318480000301
    Figure BDA0005408318480000301
Patent Text Reader

Abstract

The present invention relates to a monoclonal antibody, or an antigen-binding fragment thereof, which specifically binds to human CCR8 and is an antagonist of the CCL1-CCR8 signaling pathway, in particular an insolvable antagonist. The invention also relates to antibodies or antigen-binding fragments for use in therapy, in particular in the treatment of cancer.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Composition of antibody specifically binding to CD20

    EP1469065A1

  • Improvement in lamp-burners

    US101073A

  • Improvement in stills

    US110516A

  • Improvement in plows

    US112234A

  • Improvement in apparatus for mixing soaps, paints

    US147412A